Bevacizumab-Based Therapy Is Associated with Prolonged Progression-Free Survival in Patients with Peritoneal Mucinous Metastatic Colorectal Cancer
Journal of Clinical Medicine · 07.04.2026 · 15 (7) · 2805
DOI: 10.3390/jcm15072805 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.04.2026. Verfasst von Süleyman Can und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Çanakkale Onsekiz Mart University, Çanakkale 17100, Türkiye. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
In metastatic colorectal cancer (mCRC), mucinous histology has been associated with poor clinical outcomes, particularly in the presence of peritoneal metastasis. However, it remains unclear whether mucinous histology exerts a context-dependent effect on treatment outcomes by modifying the efficacy of anti-vascular endothelial growth factor (VEGF)-based therapies independently of metastatic dissemination patterns and chemotherapy backbone.
Methods
We retrospectively analyzed 250 patients with mCRC treated with bevacizumab-containing systemic therapy. Tumors were classified as mucinous (n = 52) or non-mucinous (n = 198). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards regression models were applied for univariate and multivariate analyses. Predefined subgroup analyses were conducted according to peritoneal metastasis status and chemotherapy backbone (oxaliplatin- or irinotecan-based). A 6-month landmark analysis was performed to reduce early progression bias. Interaction analyses evaluated potential effect modification between histology, peritoneal metastasis, and chemotherapy backbone.
Results
Mucinous tumors were more frequently right-sided and strongly associated with peritoneal metastasis. In the overall cohort, mucinous histology was associated with significantly longer median PFS compared with non-mucinous histology (22.9 vs. 11.9 months; p < 0.001). This benefit was driven by patients with peritoneal metastasis, in whom mucinous histology was associated with markedly prolonged PFS (23.9 vs. 8.7 months; p < 0.001). No significant PFS difference according to histology was observed in patients without peritoneal metastasis. On multivariate analysis, mucinous histology remained independently associated with improved PFS (HR 0.44; 95% CI 0.25–0.78; p = 0.005), an effect preserved in the landmark cohort (HR 0.39; 95% CI 0.26–0.59; p < 0.001). A significant interaction between mucinous histology and peritoneal metastasis was observed (p for interaction = 0.040), indicating that the prognostic impact of histology differed according to metastatic pattern. No significant PFS difference or interaction was detected according to chemotherapy backbone within the mucinous subgroup.
Conclusions
Among bevacizumab-treated patients with mCRC, mucinous histology—particularly in the presence of peritoneal metastasis—is associated with a pronounced PFS advantage independent of chemotherapy backbone. These findings suggest that mucinous peritoneal mCRC represents a biologically and clinically distinct subgroup that may derive context-specific and disproportionate benefit from anti-VEGF-based strategies, warranting prospective validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Çanakkale Onsekiz Mart University, Çanakkale 17100, Türkiye.
- Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Trakya University, Edirne 22030, Türkiye.
ORCID-Profile: Süleyman Can, Veli Çakıcı, Şeyma Eroğlu, Esra Özer, İvo Gökmen
Zitieren
APA
Can, S., Çakıcı, V., Kahveci, G. B., Eroğlu, Ş., Tok, B., Uygun, G., Özer, E., Çırak, Y., & Gökmen, İ. (2026). Bevacizumab-Based Therapy Is Associated with Prolonged Progression-Free Survival in Patients with Peritoneal Mucinous Metastatic Colorectal Cancer. Journal of Clinical Medicine, 15(7), 2805. https://doi.org/10.3390/jcm15072805
Vancouver
Can S, Çakıcı V, Kahveci GB, Eroğlu Ş, Tok B, Uygun G, et al. Bevacizumab-Based Therapy Is Associated with Prolonged Progression-Free Survival in Patients with Peritoneal Mucinous Metastatic Colorectal Cancer. Journal of Clinical Medicine. 2026;15(7):2805. doi:10.3390/jcm15072805
BibTeX
@article{Can2026,
author = {Can, Süleyman and Çakıcı, Veli and Kahveci, Gizem Bakır and Eroğlu, Şeyma and Tok, Burak and Uygun, Gökhan and Özer, Esra and Çırak, Yalçın and Gökmen, İvo},
title = {Bevacizumab-Based Therapy Is Associated with Prolonged Progression-Free Survival in Patients with Peritoneal Mucinous Metastatic Colorectal Cancer},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {7},
pages = {2805},
doi = {10.3390/jcm15072805}
}
EUVIMED